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Abstract 
Immunologically inert allogeneic acellular dermal scaffolds provide a matrix with 
molecular architecture close to native tissues, which synthetic scaffolds cannot.  Not all 
nature-derived scaffolds possess the same biological and physical properties.  The different 
properties of scaffolds supporting cellular growth used for manufacturing tissue engineered 
grafts could lead to different implantation results.  The scaffold properties should be 
carefully considered in order to meet the expected outcomes of tissue engineered grafts.  In 
this report, we evaluated the cellular growth on AlloDerm® and Allopatch, two acellular 
scaffolds derived from human cadaver skin, using a fabricated 3D organotypic culture with 
primary human oral keratinocytes to produce an Ex Vivo Produced Oral Mucosa 
Equivalent (EVPOME).  A well stratified epithelium could be constructed on both 
scaffolds.  AlloDerm® and Allopatch EVPOMEs were also implanted into SCID (Severe 
Combined Immunodeficiency) mice to compare the ingrowth of blood vessels into the 
dermal component of the two EVPOMEs.  Blood vessel counts were 3.3 times higher 
(p=0.01) within Allopatch EVPOMEs than within AlloDerm® EVPOMEs.  An oral and 
skin keratinocyte co-culture, separated by a physical barrier to create a cell-free zone, was 
used to evaluate cell migration on AlloDerm® and Allopatch.  Slower cell migration was 
observed on Allopatch than on AlloDerm®.   
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1. Introduction 
Soft tissue, such as oral mucosa and skin, may be necessary for reconstruction after 
surgeries for tumor removal, congenital defects (cleft lip), or by trauma.  The availability 
of the healthy autografts to repair these defects is limited.  To address this issue, we 
developed a three-dimensional (3D) in vitro organotypic culture to fabricate autogenous 
human tissue-engineered products for intraoral grafting procedures.  In addition to clinical 
applications, the in vitro 3D tissue-engineered devices can also provide cellular 
architecture that mimics the in situ native environment allowing us to study how cells 
function as parts of a whole organ. 
Scaffolds are important to support cellular growth in the manufacture of 3D tissue-
engineered products.  There are various types of scaffolds used for the 3D organotypic 
culture. (Ko et al., 2013; Garg et al., 2012; Moharamzadeh et al., 2007).  Scaffolds can be 
synthetic, such as biodegradable polymer; or non-synthetic, such as collagen-, fibrin-, or 
gelatin-based scaffolds, or naturally derived scaffolds, such as acellular human cadaver 
skin with a preserved basement membrane and the extracellular matrix of the dermis 
(Parmaksiz et al., 2016).  Acellular human cadaver skin scaffolds are immunologically 
inert with a long history of clinical applications.  Two examples of commercially available 
human cadaver skin derived scaffolds are AlloDerm® and Allopatch.  The detailed 
procedures used to produce AlloDerm® and Allopatch are different.  As a result of that, 
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the textures, physical, chemical, and biological properties of these scaffolds may be 
different from each other as the processes used by the companies to decellularize the 
dermis is proprietary.  The variability in the properties of the decellularized human dermis 
is a proponent of the process used by each company thus making it necessary to assess the 
uniqueness of the resulting material prior to clinical use.  Two physical properties of 
scaffolds, porosity and pore size, were reported to be related to cell seeding efficiency, cell 
penetration, and cell proliferation (Rodina et al., 2017; Perez and Mestres, 2016; Lee et al., 
2011; Atthoff et al., 2007).  For example, larger pore size or higher porosity of scaffold 
can enhance cell penetration.  
In our laboratory, AlloDerm® has been used to manufacture ex vivo tissue-
engineered oral mucosa products (Khmaladze et al., 2015; Kuo et al., 2015), but Allopatch 
has not.  In this report, we evaluated how cells cultured on AlloDerm® and Allopatch 
differ in terms of cellular growth and differentiation using Ex Vivo Produced Oral Mucosa 
Equivalents (EVPOMEs) as a study model (Kuo et al., 2015; Izumi et al., 1999).  To 
manufacture an EVPOME, oral keratinocytes are seeded at a high density so that the 
scaffold surface will be oversaturated with cells.  The cell development on AlloDerm® and 
Allopatch EVPOMEs was examined in vitro and in vivo.  Co-culturing oral and skin 
keratinocytes was used to create a mucocutaneous junction construct to manufacture a 
tissue engineered anal sphincter or a lip (Bayar et al., 2016; Urbanchek et al., 2016; 
Peramo et al., 2012).  We applied the principle of the co-culture of oral and skin 
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keratinocytes, separated by a physical barrier, to create an initial cell-free zone to evaluate 
how cells migrate during cellular differentiation into this zone on these two dermal 
scaffolds, AlloDerm® and Allopatch.       
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2. Materials and Methods 
2.1. Cell culture 
The University of Michigan Institutional Review Board approved all procedures of 
harvesting human oral mucosal and skin tissues.  The procedures for culturing primary 
human oral and skin keratinocytes were described previously (Bayar et al., 2016; Kuo et 
al., 2015).  Briefly, primary human oral and skin keratinocytes were enzymatically 
dissociated using 0.04% and 0.125% trypsin (Sigma-Aldrich, St. Louis, MO, USA), 
respectively, from the tissue samples, and cell cultures were established in serum free 
chemically-defined culture medium (EpiLife and EDGS, Life Technologies, Grand Island, 
NY, USA) containing 0.06 mM calcium, 25 µg/ml gentamicin and 0.375 µg/ml fungizone.  
Skin keratinocytes were cultured in medium containing 2% serum for the first 24 hours, 
and then switched to serum free medium. 
2.2. Diffusion rate analysis on Allopatch and AlloDerm® 
Allopatch (Musculoskeletal Transplant Foundation, Edison, NJ, USA) and AlloDerm® 
(LifeCell Corporation, Branchburg, NJ, USA) scaffolds were placed onto 6-well transwell 
inserts (Corning, Corning, NY, USA) in an air-liquid interface and incubated with 0.1% 
Ponceau S (Thermo Scientific, Waltham, MA, USA) for different time points (1, 3, 24, and 
48 hours). They were frozen in O.C.T. (Optimal Cutting Temperature) compound (Sakura 
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Finetek, Torrance, CA, USA) and then cut into 6 μm sections. Diffusion patterns were 
histologically evaluated.  
 
2.3. Ex vivo produced oral mucosa equivalents (EVPOMEs) manufacturing and 
histology 
AlloDerm® scaffolds were rehydrated in DPBS (Dulbecco’s phosphate buffered saline) 
without calcium chloride and magnesium chloride (Gibco by Life Technologies, Grand 
Island, NY, USA) for a total of 1.5 hours to manufacture EVPOMEs using AlloDerm®.  
Allopatch scaffolds were rehydrated in DPBS for 1.5 hours in the initial protocol, but were 
rehydrated in DPBS overnight for optimized procedures to manufacture EVPOMEs using 
Allopatch based on the results of the diffusion pattern analysis.  The manufacturing of 
EVPOMEs was reported previously (Kuo et al., 2015; Izumi et al., 2004, 1999).  Briefly, 
200,000 oral keratinocytes/cm2 were seeded on 1 cm diameter acellular Allopatch and 
AlloDerm® scaffolds that were pre-soaked in 0.05 µg/µl human type IV collagen (Sigma-
Aldrich, St. Louis, MO, USA).  EVPOMEs were submerged in medium containing 1.2 
mM Ca2+ for 4 days followed by an air-liquid phase for an additional 7 days.  Each 
EVPOME sample was fixed in 10% formalin, embedded in paraffin, cut into 5 µm sections 
and processed by the histology core at the Dental School, University of Michigan for 
hemotoxylin and eosin (H&E) staining.  Anti-Ki67 antibody (abcam, Cambridge, MA, 
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USA), used at a dilution of 1:200, was detected by 3, 3’-Diaminobenzidine (DAB) 
chromogen with hematoxylin as counterstaining.  Prior to implantation of EVPOMEs into 
severe combined immunodeficiency (SCID) mice, one-fifth of each EVPOME sample was 
removed for histology examination.  The remaining EVPOME was implanted into SCID 
mice for one and two weeks.    
 
2.4. 3D co-culture of oral and skin keratinocytes and histology 
AlloDerm® and Allopatch scaffolds (3x3 cm) were rehydrated in DPBS for 1.5 hours and 
overnight, respectively.  The scaffolds were then coated with 0.05 µg/µl human type IV 
collagen.  A 2.8 mm wide barrier was placed on top of the scaffolds to create a cell-free 
zone between the two cellular areas.  The barrier frame was made out of ABSplus plastic 
by the University of Michigan 3D Laboratory with a Dimension Elite 3D Printer 
(Stratasys, Eden Prairie, MN, USA).  The central space of the frame was filled with 
poly(dimethylsiloxane) (PDMS) (SYLGARD 184®, Dow Corning, Midland, MI, USA) 
with a ratio of base to curing agent ranging from 10 to 11 by weight.  The PDMS was 
cured for 24 hours at room temperature followed by an additional 4 hours at 65 ⁰C to 
complete curing.  The setup of 3D co-culture of oral and skin keratinocytes was shown in 
Figure 5A.  The scaffolds were then seeded with 500,000 oral keratinocytes or skin 
keratinocytes/cm2 on either side of the barrier.  Cells were cultured in medium containing 
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0.06 mM calcium.  After 24 hours, the medium was completely aspirated out before the 
barrier was removed.  From this point on, the medium used for cell culture contained 1.2 
mM calcium.  The cells on the dermal equivalent were cultured, submerged, in medium for 
4 days followed by an additional 7 days at an air-liquid phase.  At the end of culture, the 
samples were fixed in 10% formalin, embedded in paraffin, cut into 5 µm sections to 
encompass both oral and skin areas by the histology core at the Dental School, University 
of Michigan.  Anti-K2 antibody (PROGEN Biotechnik, Heidelberg, Deutschland), at a 
dilution of 1:250, and anti-small proline-rich protein 3 antibody (SPRP3, Sigma-Aldrich, 
St. Louis, MO, USA), at a dilution of 1:2000, were used to distinguish skin and oral 
keratinocytes, respectively.  Immunohistochemistry signals were detected using 3, 3’-
Diaminobenzidine (DAB) chromogen and hematoxylin as counterstaining. 
2.5. EVPOMEs grafting into SCID (severe combined immunodeficiency) mice and 
post-implanted EVPOME histology 
Mouse surgical procedures were described previously (Kuo et al., 2015; Izumie et al., 
2003).  10 AlloDerm® and 10 Allopatch EVPOMEs were grafted into 7- to 8- week-old 
SCID mice (Charles River Laboratories, Wilmington, MA, USA).  Five EVPOMEs of 
each dermal equivalent were assessed at one and two-weeks post-implantation.  Each 
grafted EVPOME was overlaid with a slightly larger sterilized 0.005 inch thickness of 
silicon sheeting (Specialty Manufacturing, Saginaw, MI, USA) to create a physical barrier 
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between the implant and overlying tissue.  Implanted EVPOMEs were removed from mice 
at one and two-weeks post-implantation.  The samples were fixed in 10% formalin, 
embedded in paraffin, cut into 5µm sections.  Anti-pan-keratin antibody (Abcam, 
Cambridge, MA, USA) (1:250 dilution) was used on EVPOME samples implanted for one 
week.  Anti-CD31 antibody (Dianova, Hamburg, Germany) (1:25 dilution) was used on 
two-week implanted EVPOME samples.  Immunohistochemistry signals were detected 
using 3, 3’-Diaminobenzidine (DAB) chromogen and hematoxylin as counterstaining.  
Blood vessels that grew into the dermal equivalent, AlloDerm® or Allopatch of the 
implanted-EVPOMEs were counted from three histology sections for each sample.  Each 
histology section contained four strips of samples that were cut out of each entire 
implanted EVPOME.   
2.6. Statistics analysis of blood vessels counts integrated into two-week implantation 
of EVPOMEs  
The experiment included five samples from each of AlloDerm® and Allopatch EVPOMEs 
and three slides per each sample.  Blood vessel counts were collected from each slide with 
a total of 30 count data (15 AlloDerm® EVPOME slides and 15 Allopatch EVPOME 
slides).  To compare the blood vessel counts between the AlloDerm® EVPOMEs and 
Allopatch EVPOMEs, a mixed-effects generalized linear model was used with log link and 
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Poisson family to account for larger variance with larger mean counts and with each 
EVOME sample as random intercepts to account for the correlation within each sample.  
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3. Results 
3.1. Three-dimensional organotypic culture on AlloDerm® and Allopatch 
The same procedures were used to manufacture AlloDerm® and Allopatch Ex Vivo 
Produced Oral Mucosa Equivalents (EVPOMEs).  We observed that there was quality 
difference between EVPOMEs using these two types of scaffolds.  The photomicrographs 
of AlloDerm® EVPOME are shown in column A and Allopatch EVPOME in column B 
(Figure 1).  H&E histology demonstrated that the AlloDerm® EVPOME has thicker 
cellular layers and keratin structure overall than the Allopatch EVPOME, which lacked 
homogeneous cellular layers and keratin (the pink area marked with K).  The 
immunohistochemistry of Ki67 showed that there were more Ki67 positive cells on the 
AlloDerm® EVPOME than on the Allopatch EVPOME.  The thickness of AlloDerm® is 
0.4 to 0.5 mm and Allopatch 0.4 to 0.7 mm according to the manufacturers’ pamphlets.  
Allopatch has wider variation of thickness overall compared with AlloDerm®.  It 
prompted us to hypothesize that the thickness of scaffolds may affect medium diffusion 
rate on AlloDerm® and Allopatch, and may play a role on how the nutrition of culture 
medium was delivered to cells residing on scaffolds/dermal equivalents.   
3.2. Evaluation of diffusion efficiency of AlloDerm® and Allopatch 
To test the hypothesis that different methods of decellularization of dermal equivalents can 
affect the physical characteristics of fluid diffusion rate in AlloDerm® and Allopatch, we 
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incubated the AlloDerm® and Allopatch on an air-liquid interface with a dye, Ponceau S, 
for various time points.  The results are shown in Figure 2.  We noticed that the dye 
diffusion patterns were similar between these two types of scaffolds.  That is, the side edge 
was infiltrated with dye before the inner area.  However, Ponceau S dye stained the whole 
piece of AlloDerm® at the end of 24 hours, while the dye had not reached the top of the 
Allopatch even after a 48-hour incubation.  We used the scale bar to measure the diffusion 
distance of dye on inner area of scaffolds at various time points.  The diffusion rates were 
calculated by diffusion distances and their corresponding time points.  The average of 
diffusion rate for each time point was calculated based on three histology sections.  The 
diffusion rates are for AlloDerm®: 1-hour time point, 30.8 µm/hr; 3-hour time point, 19 
µm/hr; for Allopatch: 1-hour time point, 87 µm/hr; 3-hour time point, 83.3 µm/hr; 24-hour 
time point, 16.1 µm/hr; 48-hour time point, 6.9 µm/hr.  We did not calculate the diffusion 
rates of 24- and 48-hour time points for AlloDerm® because the dye already reached the 
top of AlloDerm® at 24-hour time point as shown in Figure 2.  The higher diffusion rates 
of Allopatch than AlloDerm were found at shorter time points; however, the much lower 
diffusion rates of Allopatch were found at longer time points when compared to shorter 
time points of Allopatch.       
3.3. Three-dimensional organotypic culture on Allopatch with procedures of 
increasing diffusion efficiency 
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Based on the results of diffusion efficiency, we suspected that the cellular stratification of 
the Allopatch EVPOME could be improved if we increased the diffusion rate of the dermal 
equivalent, Allopatch.  Allopatch was rehydrated in DPBS for 24 hours instead of 1.5 
hours before cell seeding.  The result of an EVPOME using extended DPBS soaking time 
is shown in Figure 1 column C.  The stratified cellular layers and keratin structure were 
significantly improved, and there was an increase in Ki67 positive cells when compared 
with Allopatch EVPOME (Figure 1 column B) that was manufactured with 1.5 hours 
soaking based on multiple repeated experiments.    
3.4. Evaluation of in vivo development of implanted AlloDerm® and Allopatch 
EVPOMEs  
The success of an implanted graft depends on its continuous in vivo maturation and how 
well it integrates into host tissue and develops a vascular supply within the dermal 
equivalent to nourish the overlying epithelium.  In light of that, following the successful in 
vitro quality improvement of Allopatch EVPOMEs, we evaluated and compared the 
implanted in vivo development of both implanted AlloDerm® and Allopatch EVPOMEs. 
The results of ten EVPOMEs (five AlloDerm® and five Allopatch EVPOMEs) 
implanted into severe combined immunodeficiency (SCID) mice for one week are shown 
in Figure 3.  AlloDerm® and Allopatch EVPOMEs before implantation are shown on the 
left column (in vitro H&E) and their corresponding one week implanted EVPOMEs are 
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shown in the middle (in vivo H&E) and right (in vivo pan-keratin IHC) columns.  Anti-
pan-keratin antibody was used to detect continuous stratification of cellular layers and 
expression of keratin to evaluate reepithelization on one-week implanted EVPOMEs.   We 
observed similar epithelialization patterns on both one week implantations of AlloDerm® 
and Allopatch EVPOMEs. 
To examine the integration of implanted EVPOMEs into host tissue, we used anti-
CD31 antibody to detect the blood vessels ingrown into the dermal equivalents of two-
week implanted EVPOMEs.  The distribution of blood vessel counts from the in vivo 
experiment is shown in Figure 4A where higher blood vessel counts were seen for 
Allopatch EVPOME samples than AlloDerm® EVPOME samples.  The comparison of 
mean counts using the mixed-effects generalized linear model showed 3.3 times (95% 
confidence interval = 1.3, 8.4, p = 0.01) higher counts in Allopatch EVOME samples 
compared with AlloDerm EVPOME samples.  The representative pictures of CD31 
immunohistochemistry are shown in Figure 4B. 
3.5. Evaluation of in vitro cellular migration on AlloDerm® and Allopatch  
By extending the DPBS soaking time on Allopatch, we could manufacture Allopatch 
EVPOMEs with cellular structure comparable to AlloDerm® EVPOMEs in vitro.  Our 
EVPOMEs in vivo study also demonstrated that both implanted AlloDerm® and Allopatch 
EVPOMEs had similar epithelialization patterns.  These results demonstrated the 
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stratification of cellular growth on AlloDerm® and Allopatch EVPOMEs were comparable 
to each other when both were seeded with high cell density (200,000 cells/cm2).  We were 
interested in how the cellular migration would progress on these two different types of 
scaffolds for manufacturing a mucocutaneous junction construct.  To examine this 
phenomenon, we created a cell-free zone by placing a barrier on top of the scaffold/dermal 
equivalent.  Oral and skin keratinocytes were then seeded on both external sides of the 
barrier creating an internal cell-free zone.  Cells were allowed to merge or migrate towards 
one another gradually after the barrier was removed 24 hours after cell seeding.  The set-up 
of this culture is shown in Figure 5A.  The width of the barrier was 2.8 mm.  We used a 
biomarker, small proline-rich protein 3 (SPRP3), which was specific for oral keratinocytes 
(Bayar et al., 2016; Katou et al., 2003).  The biomarker, cytokeratin protein K2, was used 
to identify skin keratinocytes specifically based on The Human Protein Atlas web site 
(http://www.proteinatlas.org).  We checked the expression of K2 on both native skin and 
gingivae tissues, and found K2 only expressed in skin, but not in gingivae (data not 
shown).  The total culture time for both AlloDerm® and Allopatch three dimensional 
organotypic oral/skin co-cultures was 12 days.  The results are shown in Figures 5B and 
5C.  We observed that the oral and skin keratinocytes could merge/migrate towards one 
another at the end of 12 days culture on AlloDerm® (Figure 5B); however, there was still a 
cell-free gap between oral and skin cells on Allopatch (Figure 5C).  This result indicated 
that cells proliferated or migrated slower on the surface of Allopatch than on AlloDerm®; 
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and it would require more culture time for Allopatch to fill the cell-free zone than 
AlloDerm®.      
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4. Discussion 
It is critical to choose the appropriate scaffold with ideal physical properties, such as 
biocompatibility and porosity, to ensure the success of tissue engineering products in hosts.  
Natural derived scaffolds can offer molecular complexity and architecture of the native 
tissue matrices to support cellular growth that synthetic scaffolds cannot for tissue 
engineering products.  However, the natural derived scaffolds from decellularized human 
cadaver skins do not warrant the same outcomes of cellular development on these 
scaffolds, because they may possess different physical and biology properties (Luo et al., 
2015; Barber and Aziz-Jacobo, 2009)  produced with proprietary manufacturing 
procedures by different companies.  We used Ex Vivo Produced Oral Mucosa Equivalents 
(EVPOMEs) as a study model (Kuo et al. 2015, Izumi et al., 1999) to evaluate how 
cultured keratinocytes developed on two allogeneic natural human decellularized scaffolds, 
AlloDerm® and Allopatch.   
It is appropriate to suggest that the quality of 3D tissue engineering products using 
AlloDerm® and Allopatch as scaffolds should be the same or similar to each other.  
Unexpectedly, our data showed that AlloDerm® and Allopatch EVPOMEs carried very 
different in vitro cellular development and diffusion results.  Rete pegs could be observed 
on both EVPOMEs; however, the lack of cellular structures or thinner cellular layers 
between rete pegs on Allopatch EVPOMEs was obvious.  In addition, Allopatch 
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EVPOMEs had a lower density of Ki67 positive cells.  Kato et al. (2015) reported that the 
thickness of scaffolds could affect the outcome of EVPOMEs due to different medium 
diffusion rates among various scaffolds thicknesses.  The thickness of AlloDerm® is 0.4 to 
0.5 mm and Allopatch 0.4 to 0.7 mm.  Allopatch has less homogenous thickness compared 
with AlloDerm®, which could cause the outcomes that we observed histologically.  The 
much lower diffusion rates of Allopatch at longer time points suggested that molecules 
were more difficult to move up when they were close to the epidermal (cell seeding) side.  
Our dye, Ponceau S, diffusion rate results supported that different medium diffusion rates 
could cause the thin cellular layers on Allopatch EVPOME.  After improving the diffusion 
rate on Allopatch by soaking for an extended period of time, we could produce Allopatch 
EVPOMEs with a well-stratified epithelial layer and rete ridge structure similar to 
AlloDerm® EVPOMEs.  The same was true of the implanted tissue engineered grafts (Kuo 
et al., 2015; Yoshizawa et al., 2012; Izumi et al., 2003).  Previously, we reported that the 
expression of glucose transporter 1, GLUT1, and the consumption of glucose were reduced 
in the poorly developed EVPOMEs (Kato et al. 2015).  It suggests that glucose is the 
potential diffusion molecule affected by the diffusion rate.  The manipulation of Allopatch 
to increase medium diffusion rate is critical to produce a high quality EVPOME and to 
optimize its post-implant cellular development.   
Scaffold porosity and pore size can affect cell penetration, and cell proliferation 
(Rodina et al., 2017; Perez and Mestres, 2016; Lee et al., 2011).  Larger pore size or higher 
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porosity of scaffold can enhance cell penetration.  It is possible that the physical properties 
on the basal membrane side (cell seeding side) of Allopatch can be affected by longer 
rehydration time.  Cell penetration can be improved if pore sizes are larger or porosity is 
higher on the basal membrane side of Allopatch following longer rehydration time.  It is 
also possible that a longer rehydration time of Allopatch can improve the interaction with 
later coated collagen thus increases the cell seeding efficiency and cell proliferation on 
Allopatch.  We experimented 24-hour rehydration time twice on AlloDerm®, but we did 
not observe significant improvement of cellular stratification on AlloDerm® EVPOME.  
However, we cannot exclude the possibility that the harmful residues left behind in 
Allopatch during the decellularization process was removed after longer rehydration time, 
which improved the quality of Allopatch EVPOME.  
Neovascularization is a crucial factor to determine the success of the implanted 
tissue engineered grafts (Kuo et al., 2015; Izumi et al., 2013, Iida et al., 2005).  Higher 
blood vessel counts were seen for Allopatch EVPOME samples than AlloDerm® 
EVPOME samples.  Luo et al. (2015) suggested that a possible factor that could contribute 
to the difference of neovascularization between AlloDerm® and Allopatch EVPOMEs was 
the variation of the dense fibrous tissue between AlloDerm® and Allopatch.  Based on 
histology morphology, Allopatch possesses a less dense collagen matrix as shown in dye 
diffusion histology, which could allow easier invasion of blood vessels into Allopatch.  In 
other words, Allopatch may have better porosity than AlloDerm® that allows adequate 
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intrinsic vascularization (Will et al., 2008).  The combination of various freeze drying 
process and collagen concentrations may lead to different pore sizes in scaffolds 
(Madaghiele et al., 2008; Faraj et al., 2007).  We suspect that the different freezing 
temperatures and, possible, solute concentrations used to process the human cadaver skin 
are different between manufacturing Allopatch and AlloDerm®.  Since both 
decellularzation protocols are proprietary we could not compare the two different 
processes. 
By combining the extended soaking time of DPBS on Allopatch with a high cell 
seeding density to saturate the scaffold, we could manufacture an equivalent quality of 
AlloDerm® and Allopatch EVPOMEs.  This suggests that a scaffold can execute cellular 
differentiation/stratification when a certain level of medium diffusion rate is met.  
However, our 3D tissue engineered products using an oral and skin keratinocytes co-
culture system showed that the medium diffusion rate may not be the only factor related to 
cell migration on certain scaffolds, such as Allopatch in our study.  Kim et al. (1994) 
showed that type IV collagen surface could enhance both keratinocyte attachment and 
migration.  Both AlloDerm® and Allopatch were coated with type IV collagen in our 
culture system.  The scaffold surface molecular structure could be damaged during the 
decellularization manufacturing process, which could affect the contribution of collagen to 
cell migration on the scaffold surface.  This might affect Allopatch more than AlloDerm®.   
One may propose that the increase of culture time should allow gaps to be filled on 
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Allopatch EVPOMEs.  However, a lengthy culture time does not always parallel the 
quality of 3D tissue engineered products (Izumi et al., 2003, 2004). 
The goal of a tissue engineered product is allowing the graft to be integrated into 
the host quickly to maintain cell viability and providing a regenerated tissue with similar 
native structure and function.   An adequate formation of blood vessels on an implanted 
graft is required to allow the above phenomena to happen.  Allopatch could be an 
advantageous choice compared with AlloDerm®, since there are more blood vessels 
formed within Allopatch than AlloDerm®.  On the other hand, when cell migration is 
expected to happen in a timely manner on the scaffold surface, then Allopatch may lose its 
competitive edge to AlloDerm® when ex vivo tissue engineered products are executed.  
Our in vitro and in vivo data showed that not all natural derived scaffolds are equal in all 
perspectives regardless of their common source.  The biology and physical properties of 
various scaffolds should be carefully considered in making the appropriate choice in order 
to meet the expected outcomes of tissue engineered grafts.  
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Figure Legends 
Figure 1.  Representative pictures of H&E histology and Ki67 immunohistochemistry of 
EVPOMEs using AlloDerm® (D) and Allopatch (P) as scaffolds.  Column A shows the 
AlloDerm® EVPOME.  Columns B and C show the Allopatch EVPOMEs manufactured 
by the same procedures as for AlloDerm® EVPOMEs and modified procedures, 
respectively.  Scale bars in the H&E row are 50 µm, Ki67 row 100 µm.  The keratin layer 
is marked by a K and an arrow on H&E pictures.  The brown spots on the epidermal area 
of EVPOMEs on the Ki67 row are positive signals of Ki67. 
 
Figure 2.  Histology pictures of diffusion rate patterns of 0.1% Ponceau S on AlloDerm® 
and Allopatch at different time points. Scale bars represent 200 µm. 
 
Figure 3.  Evaluation of in vivo development of implanted AlloDerm® and Allopatch 
EVPOMEs.  Before (in vitro) and corresponding one week after (in vivo) EVPOMEs 
implantation are shown in H&E and pan-keratin immunohistochemistry (IHC) (only in 
vivo shown for pan-keratin IHC).  Red arrows indicate the areas of continuous 
development of implanted EVPOMEs examined by anti-pan keratin antibody.  D 
represents AlloDerm®, and P Allopatch.  Scale bars represent 50 µm. 
This article is protected by copyright. All rights reserved.
 
Figure 4.  Statistical data of neovascularization and CD31 immunohistochemistry pictures 
of implanted AlloDerm® and Allopatch EVPOMEs.  (A). The distribution of blood vessel 
counts.  (B). Representative pictures of neovascularization within implanted EVPOMEs 
detected by anti-CD31 antibody shown in brown.  D and P represent AlloDerm® and 
Allopatch, respectively. Scale bars represent 50 µm. 
 
Figure 5.  3D organotypic co-culture of oral and skin keratinocytes.  (A). The setup of skin 
and oral keratinocytes co-cultured on scaffold.  O is oral keratinocyte culture area and S 
skin keratinocyte culture area.  The barrier placed on top of a scaffold was used to create 
an initial cell-free zone during the first 24 hours of culture.  (B) and (C). H&E, SPRP3, and 
K2 histology pictures of the oral and skin keratinocytes co-cultures on AlloDerm® (Figure 
5B) and Allopatch (Figure 5C).  Sections next to each other were shown for each 3D 
culture sample.  O represents oral keratinocytes side and S skin keratinocytes side.  Red 
arrows represent the points of maximum migration of either oral or skin keratinocytes on 
AlloDerm® marked by D, or Allopatch marked by P.  Oral and skin keratinocytes merged 
after successful migration towards each other on AlloDerm®, while there is a cell-free gap 
on Allopatch.  Scale bars represent 250 µm.  
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